RESUMEN
In this study, an environmentally sustainable fluorimetric method for determination of Vonoprazan fumarate (VON) in dosage forms using nanoprobes consisting of nitrogen and sulfur co-doped carbon quantum dots (N, S-CQDs). The N, S-CQDs were prepared through a microwave-assisted method in 30 s. The resulting N, S-CQDs were characterized using transmission electron microscopy (TEM), high-resolution transmission electron microscopy (HRTEM), Fourier transform infrared spectroscopy (FTIR), and X-ray photoelectron spectroscopy (XPS). They exhibit fluorescence emission at 460 nm after excitation at 385 nm with a high quantum yield (60%). The analytical approach for VON determination relies on the quenching effect exerted by VON on the native fluorescence intensity of CQDs. The quenching mechanism was investigated using Stern-Volmer plots. The proposed method demonstrates linearity across a concentration range 10-80 µM (4.6-36.8 µg/mL) with corresponding limits of detection and quantitation calculated as 2.17 µM (0.99 µg/mL) and 6.58 µM (3.02 µg/mL), respectively. The method has been effectively utilized for the determination of VON in the pharmaceutical samples. Statistical comparison with reported RP-HPLC has been performed to verify the accuracy and precision of the developed method. The environmental sustainability of the developed method has been thoroughly examined through various greenness metrics.
Asunto(s)
Carbono , Fluorometría , Nitrógeno , Pirroles , Puntos Cuánticos , Sulfonamidas , Azufre , Puntos Cuánticos/química , Nitrógeno/química , Sulfonamidas/química , Sulfonamidas/análisis , Carbono/química , Pirroles/química , Azufre/química , Espectrometría de FluorescenciaRESUMEN
The purpose of this study is to develop a novel method for synthesizing silver nanoparticles using glucosamine as reducing agent and to utilize the developed method for colorimetric detection and quantitative determination of the non-chromophoric drug, glucosamine. Silver nanoparticles are prepared by reducing 0.02 mol/L silver nitrate by glucosamine in 0.075 mol/L ammonia and stabilizing the nanoparticles with 0.1% polyvinylpyrrolidone and the mixture is heated at 90 °C for 5 min. The prepared silver nanoparticles dispersed in water exhibit a bright yellow color due to a localized surface plasmon resonance band at 412 nm. The principle of glucosamine sensing is based on measuring the intensity of the surface plasmon resonance band at 412 nm which is directly proportional to the concentration of glucosamine with a linearity range (1 - 9 µg/mL), limit of detection 0.33 µg/mL and limit of quantitation 1.0 µg/mL. The proposed method was validated according to the ICH guidelines, and it was found to be accurate, precise, selective, and robust. The method was applied for determination of glucosamine in Joflex® capsules using the standard addition approach with mean % recovery ± standard deviation of 100.077 ± 1.786. The method is simple, rapid, and cost-effective and can be used for determination of glucosamine in bulk and in its pharmaceutical preparations.
RESUMEN
The purpose of this study is to develop a dual fluorescence-colorimetric sensor for determination of the non-chromophoric drug, tobramycin using fluorescein-modified silver nanoparticles. Fluorescein is adsorbed on the surface of silver nanoparticles resulting in quenching of the fluorescence intensity of fluorescein at 513 nm. Upon addition of tobramycin to fluorescein-bound silver nanoparticles, tobramycin can displace fluorescein from the surface of nanoparticles resulting in nanoparticles aggregation and liberation of free fluorescein restoring its fluorescence. The interaction of tobramycin with fluorescein-bound silver nanoparticles is manifested by a decrease in the surface plasmon resonance band of silver nanoparticles at 395 nm, an increase in the fluorescence intensity of fluorescein at 513 nm and color change of the colloidal solution from yellow to light pink. These spectral effects are directly proportional to the concentration of tobramycin with a linearity range of 0.10 - 0.45 µg mL-1 and 0.05 - 0.45 µg mL-1 for the spectrophotometric and spectrofluorimetric methods, respectively. The proposed methods were applied for determination of tobramycin in Tobrin® ophthalmic solution with mean %recovery ± standard deviation of 99.036 ± 1.737 for the spectrophotometric method and 101.192 ± 1.315 for the spectrofluorimetric method. The optical sensor is simple, rapid, and cost-effective and can be used for determination of tobramycin in bulk and in its pharmaceutical preparations.